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The only previously published case of anti-G in a pregnant woman
indicated that anti-G alone caused little, if any, fetal or neonatal
hemolysis. This report describes an affected fetus with amnionitic
fluid OD 450 absorbance values in the moderate zone of the Liley
prediction graph who required prolonged phototherapy after birth
until day of life 20. Anti-G was identified and anti-C and -D excluded
in the mother’s serum. In contrast to the previous report, this
report shows anti-G alone can cause moderate HDN and that fetal
monitoring and treatment may be necessary.
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Antibodies to the antigens in the Rh system are
well-known causes of HDN. The D antigen is a very
potent immunogen and anti-D can cause severe HDN.
Anti-C has also been shown to cause HDN, although
generally less severe. First elucidated by Allen and
Tippett in 1958, the G antigen is present on almost all
D+ or C+ RBCs and absent from virtually all RBCs that
are D– and C–.1 The apparent codistribution of the G
antigen with either the C or D antigen causes anti-G to
appear serologically as anti-C plus anti-D activity.1 Issitt
and Tessel were the first to use a serial double-elution
procedure using D+C– RBCs followed by D–C+ RBCs
to identify the presence of anti-G in approximately 30
percent of sera with anti-C+D activity.2 Case series
have shown that anti-D is absent in 10 of 22 (45%)3 and
2 of 7 (30%)4 of alloimmunized pregnant women with
apparent anti-D plus anti-C. Although it appears that a
significant proportion of apparent anti-D plus anti-C is
because of the presence of anti-G, the significance of an
apparent titer of anti-D actually due to anti-G in
predicting the severity of HDN is not known. The only
previously published case of a pregnant woman with
anti-G having a titer of 16 against R2R2 RBCs suggested
that anti-G alone had caused practically no fetal or
neonatal hemolysis.5 We report a case of moderate
HDN because of anti-G alone with a titer of 8 against
R2R2 RBCs where increased amniotic fluid OD 450 nm
absorbance values in the moderate zone of the Liley
prediction graph and normal middle cerebral artery
Doppler studies were followed by postpartum
hyperbilirubinemia, anemia, and the requirement for
prolonged phototherapy until day of life 20.
Case Report
A 31-year-old group O, rr (dce/dce), gravida 5
pregnant woman was referred to the maternal-fetal
medicine department at our facility at 17 weeks, 6 days
gestational age because of a history of recurrent
spontaneous abortions. Prenatal antibody screening test
results from the referring hospital had revealed anti-C
and anti-D with titers of 64 and 32, respectively. The
patient had received Rh immunoglobulin (RhIG)
prophylaxis after all procedures and abortions except
for a spontaneous abortion at 6 weeks’ gestation before
the current pregnancy. She denied ever receiving a
blood transfusion. Because of her history of multiple
pregnancy losses and a positive antinuclear antibody
screen, the patient was placed on prophylactic
subcutaneous heparin. Fetal middle cerebral artery peak
systolic velocity (MCA PSV), measured by ultrasound
Doppler at 21 weeks’, 6 days’ gestation, was below the
median value for gestational age, suggesting no
significant fetal anemia. Given these findings, amnio-
centesis was not performed and the patient was
instructed to return in three weeks. The patient
returned at 25 weeks, 1 day gestational age, at which
time it was noted that fetal growth lagged established
dating by two weeks. However, MCA PSV was still
without evidence of fetal anemia and there was no
I M M U N O H E M A T O L O G Y, V O L U M E 2 2 , N U M B E R 4 , 2 0 0 6 167
HDN due to anti-G
evidence of hydrops by ultrasound. The patient was
offered amniocentesis to rule out chromosomal anomaly
as the etiology for fetal growth restriction.Amniotic fluid
was also analyzed for ∆OD450 which was 0.120. This
value is in the lower portion of the affected zone of
OD450 curve by Queenan,
6 which is valid for pregnancies
earlier than 27 weeks’ gestation. These results suggest
that the fetus was affected with HDN but was not
severely anemic. Serial amniocentesis at 28, 30, and 32
weeks all returned with ∆OD450 values in the low-
affected zone of the Queenan chart and low zone 2 of
the Liley chart while MCA PSV values also remained
within the normal range, suggesting no worsening fetal
hemolysis or anemia. The fetus was also followed for
asymmetric intrauterine growth restriction by serial
ultrasound. The decision was made to deliver the fetus
by Caesarean section at 33 weeks’ gestational age
secondary to oligohydramnios with an amniotic fluid
index of 3.4 cm (normal 5–25 cm) and absent end-
diastolic flow in the umbilical artery on Doppler
ultrasound. A viable male infant weighing 1300 g with
APGAR scores of 8 and 9,whose RBCs typed as group O,
D+C+E–c+e+,was delivered. The physical exam showed
no ascites or peripheral edema. A peripheral serum
sample collected on day 1 of life showed a bilirubin of
3.6 mg/dL (1.0–10.5 mg/dL),Hb of 15.7 g/dL (13.5–19.5
g/dL), and Hct of 47.3% (42–60%). Phototherapy was
initiated with a preliminary diagnosis of moderate HDN.
While on phototherapy, the bilirubin would decrease,
maintaining levels below 10 mg/dL. However, when
phototherapy was discontinued, the bilirubin would
increase, reaching a maximum of 18.1 g/dL on day of life
13. The direct bilirubin level was consistently between
0.0 and 0.1 mg/dL,supporting an absence of obstructive
liver disease. On day of life 20, phototherapy was
stopped and the bilirubin remained stable at 16.5 to 16.7
mg/dL over the course of six days until it started to
decrease. The Hb and Hct continually declined to values
of 8.8 gm/dL (10.0–18.0 gm/dL) and 25.7% (31–55%),
respectively, on day of life 30.The neonate received no
exchange transfusions or RBC transfusions. At a follow-
up visit at age 3 months, the infant’s Hb and Hct were
11.5 g/dL and 34.6%, respectively and the infant was not
jaundiced. The mother received RhIG prophylaxis
before discharge.
Materials and Methods
A peripartum maternal serum sample was used to
determine antibody specificity and titers. The
specificity testing was performed at the American Red
Cross Blood Services,Greater Chesapeake and Potomac
Region reference laboratory. The serum was first tested
to determine initial reactivity to R1R1 (DCe/DCe)
commercial reagent RBCs and to exclude other
clinically significant antibodies by both LISS- and PEG-
AHG, according to the manufacturer’s protocol
(Panocell and Gamma PEG, ImmucorGamma, Houston,
TX; ORTHO Antibody Enhancement Solution, Ortho-
Clinical Diagnostics, Raritan, NJ). The sample was
tested against rare rGr RBCs. The patient’s serum was
then adsorbed onto ficin (Sigma-Aldrich, St. Louis,MO)-
treated r′r′ (dCe/dCe) donor RBCs five times to adsorb
anti-C, anti-G, or both to exhaustion. The absorbed
serum was tested against two R0r (Dce/dce) reagent
RBCs. The eluate prepared from the first adsorbing
aliquot of r′r′ (dCe/dCe) RBCs was adsorbed onto ficin-
treated R2R2 (DcE/DcE) donor RBCs to adsorb out anti-
G, if present (Gamma ELU-KIT II, Gamma Biologicals,
Inc., Houston, TX). The absorbed eluate was tested
against two r′r′ (dCe/dCe) reagent RBCs. Titrations
were performed on the anti-C and anti-D using r′r′
(dCe/dCe) and R2R2 (DcE/DcE) reagent RBCs
(Immucor) and a saline-AHG method with 1-hour
incubation at 37°C.
The DAT (Anti-IgG, Murine Monoclonal Gamma-
Clone, ImmucorGamma, Norcross, GA) was performed
on the infant’s cord blood sample that was manually
washed 6 times. The eluate was tested against an
antibody identification panel (Panocell–16, Immucor)
to identify anti-D and anti-C activity and to exclude
other clinically significant antibodies.
ABO and Rh typing of RBC samples from the
mother and infant were performed with monoclonal
reagents according to manufacturers’ instructions
(Immucor and Gamma Biologicals, Inc.).
Results
Testing of the patient’s serum and of the eluate
from the infant’s cord blood sample with selected
panel RBCs revealed reactivity with R1R1 (DCe/DCe)
RBCs and excluded other clinically significant
antibodies. Testing with rGr, D–G+ RBCs was strongly
reactive. After antibody adsorption from the patient’s
serum with ficin-treated r′r′ (dCe/dCe) donor RBCs,
reactivity against R0r (Dce/dce) RBCs was not detected,
excluding the presence of anti-D. An eluate prepared
from the r′r′ (dCe/dCe) adsorbing RBCs showed no
reactivity with r′r′ (dCe/dCe) RBCs after adsorption of
anti-G with ficin-treated R2R2 (DcE/DcE) RBCs, thereby
excluding the presence of anti-C. Using this double-
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elution procedure and eliminating contributions from
anti-C or anti-D through serial adsorptions, it was
shown that anti-G alone was responsible for the
reactivity with R1R1 (DCe/DCe) RBCs and r
Gr RBCs
(Table 1). The anti-G titer with r′r′ (dCe/dCe) RBCs was
16; the titer with R2R2 (DcE/DcE) RBCs was 8. The DAT
of the infant’s RBCs was 3+ and the eluate
demonstrated 3+ reactivity with R1R1 (DCe/DCe), r′r
(dCe/dce), and r′r′ (dCe/dCe) RBCs, 2+ reactivity with
R0r (Dce/dce) and R2R2 (DcE/DcE) reagent RBCs and no
reactivity with seven different r′′r (dcE/dce) and rr
(dce/dce) reagent RBCs.
Discussion
Most cases of HDN associated with anti-G have
been in association with anti-D, anti-C or both.4,5,7–9
Cash and colleagues5 described the first case where
anti-G alone was identified as the cause of a positive
DAT in an infant which resulted in the absence of
clinical evidence of HDN. In their case report, the
newborn did not require transfusion and the bilirubin
reached a peak of 11.9 mg/dL at day of life 4. Although
the presence of anti-C was not definitively excluded in
the mother, the newborn’s RBCs were C–. The titer of
the antibody was 64 against r′r RBCs and 16 against
R2R2 RBCs. They concluded that anti-G alone without
anti-C, anti-D, or both may not be sufficient to cause
severe HDN and suggested the question of whether
identification of anti-G and exclusion of anti-C and anti-
D could indicate a benign clinical course and alter
clinical management such that amniocentesis would
not be indicated.
The clinical significance of anti-G remains
controversial. Palfi et al.10 identified anti-G+C in 4 of 27
samples in their study of alloimmunized pregnant
women, none of which caused severe HDN. They
proposed that low concentration of antibody, the
occurrence of IgM antibodies, or both, were possible
explanations for this finding. In agreement with the
case reported by Cash et al.,5 they concluded that anti-
G+C alloimmunization may have a decreased risk of
HDN. This has been disputed by others. Hadley et al.7
reported a case of severe HDN due to anti-G+C in a D–
infant with anemia who required multiple exchange
transfusions. The levels and functional activities of
both anti-G and anti-C were evaluated with the IAT, the
chemiluminescence test (CLT), and flow-cytometric
techniques. They found that 6 of 7 anti-G-containing
eluates bound higher levels of IgG anti-G to r′r (C+)
RBCs than to R2r (D+) RBCs, which paralleled their
results using flow-cytometric analysis. Using the CLT,
they found the response of r′r (C+) RBCs sensitized
with an eluate containing anti-G (69%) to be consistent
with severe HDN. However, r′r (C+) RBCs sensitized
with anti-C after adsorption with R2R2 RBCs showed a
weak CL response that was not consistent with HDN.
They also tested 28 serum samples from alloimmu-
nized pregnant women with over 5 IU/mL anti-C+D
with 2 of 28 containing levels of anti-G that were
consistent with moderate to severe HDN by the CLT.
They concluded that anti-G may cause moderate to
severe HDN in those women with greater than 5 IU/mL
anti-C+D (approximately 7%) and that HDN caused by
anti-G is probably not rare. Similarly Lenkiewicz et al.8
reported a case of moderate HDN due to anti-G+C in a
D–C+ newborn with hyperbilirubinemia requiring
phototherapy. The levels and functional activities of
both anti-G and anti-C were evaluated with the IAT and
the CLT. Their results showed both the level and the
functional activity of anti-G to be greater than those of
anti-C. They concluded that anti-G, and not anti-C, was
responsible for the moderate HDN and that anti-G
should be regarded as clinically significant in the
alloimmunized pregnant woman.
We report a second case of HDN caused solely by
anti-G but in an infant who expressed both the C and
D antigens on his RBCs. By using a serial double-
elution procedure, we identified anti-G alone as the
sole antibody present. Differential adsorption
techniques were performed, excluding the possibility
of a concomitant anti-D or anti-C contributing to the
hemolysis. In our case, hyperbilirubinemia requiring a
Table 1. Adsorption and elution procedure
Sample Panel RBCs Results Conclusion
Peripartum R1R1 (DCe/DCe) Strongly Anti-C, D, or G
maternal reactive present
serum sample
Peripartum rGr Strongly Anti-G present
maternal serum reactive (+/– Anti-C or D)
sample
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prolonged stay in the hospital for phototherapy argues
that anti-G alone is sufficient to cause at least a moder-
ate HDN in an infant that expresses both the D and C
antigens on his RBCs. However, it would seem that
differentiation of anti-G from anti-D and anti-C would
not be relevant for decisions of patient monitoring.
Our case suggests that differentiating anti-D plus
anti-C from anti-G may not be relevant for the purpose
of suggesting an indication for amniocentesis given the
increasing availability of MCA PSV to predict fetal
anemia. Recent articles have suggested that MCA PSV
may be superior to amniotic fluid ∆OD450 for the
diagnosis of fetal anemia in cases of RBC alloimmu-
nization in the hands of an experienced ultrasonog-
rapher11,12 and many centers have now replaced serial
amniocentesis using ∆OD450 with serial MCA Doppler.
In our case, despite the fact that the patient was
referred to our institution with an anti-D titer of 32 and
anti-C titer of 64,which would be considered critical if
performed in our lab, a decision was made to not
perform amniocentesis because of the reassuring MCA
PSV results. Only later, when the patient had an
additional indication for amniocentesis,was the ∆OD450
measurement made. The patient was then followed for
the remainder of her pregnancy with both MCA PSV
and amniocentesis, the results of which indicated a
stable level of hemolysis without the development of
significant anemia.
Despite the noninvasiveness and increased
availability of MCA PSV, current recommendations still
do not consider use of this modality until a critical titer
is reached. Thus, titration of the antibodies is a critical
step, although, in cases of anti-D plus anti-C, the critical
titer is not known. Complicating this situation is the
fact that, although review articles would make one
tend to believe that the situation with anti-D is well
established where defined titers (3212 or 8 to 3213) are
recommended and standard methodology is
recommended (use of R2R2 reagent RBCs
13),
laboratories are still reporting widely discrepant results
as our case illustrates (referral laboratory titer result of
64 vs. our result of 8). Further complicating the
situation with anti-D plus anti-C is the variation in the
phenotype of the RBCs used to determine and
compare the anti-D and anti-C titers (R2R2 and r′r,5,7,13
R2R2 and R1R1,
3 R0r and r′r RBCs2,4,9,10). The
recommendations of the subcommittee of the
Scientific Section Coordinating Committee of the AABB
recommended the use of r′r and R2R2 RBCs when
comparing the titer of anti-C with anti-D,13 although we
used r′r′ RBCs and R2R2 RBCs in the interest of
comparing RBCs that would have more comparable
(homozygous) expression of antigens. In commenting
on the comparability of our anti-D titer result to other
labs, we think it is relevant that we have been
participating in the College of American Pathologists
Survey of anti-D titers and our results have been
consistent with the largest peer groups. Therefore,we
think our titer result would likely be consistent with
most labs that participated in this survey. Hopefully,
increased participation in titer proficiency surveys will
improve the consistency of titer results among
laboratories and facilitate comparison of titer results in
case studies.
Finally, although we do not feel that identifying
anti-G and excluding anti-D and anti-C has relevance in
deciding whether or not to nonserologically monitor a
pregnancy for HDN, especially with the availability of
MCA PSV, we agree with the recommendations of
Shirey et al.4 that identifying or excluding anti-D is
relevant. One study has indicated that although anti-G
seems to mask the antigenic sites of C and D, it does
not prevent the eventual development of anti-D,
meaning that RhIG would be indicated in a patient
with anti-G but without anti-D.9 Also, there are
medicolegal reasons for the exclusion of anti-D, such as
excluding questions of paternity for a D– couple,
avoiding inadequate prophylaxis with RhIG, and
avoiding confusion regarding previous transfusion
history as anti-G and anti-C can be found in recipients
of D– products.9,10
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